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Abstract: Mesenchymal stem cells derived from human bone marrow (hBM-MSCs) are utilized in
tendon tissue-engineering protocols while extra-embryonic cord-derived, including from Wharton’s
Jelly (hWJ-MSCs), are emerging as useful alternatives. To explore the tenogenic responsiveness of
hBM-MSCs and hWJ-MSCs to human Growth Differentiation Factor 5 (hGDF-5) we supplemented
each at doses of 1, 10, and 100 ng/mL of hGDF-5 and determined proliferation, morphology and
time-dependent expression of tenogenic markers. We evaluated the expression of collagen types 1
(COL1A1) and 3 (COL3A1), Decorin (DCN), Scleraxis-A (SCX-A), Tenascin-C (TNC) and Tenomodulin
(TNMD) noting the earliest and largest increase with 100 ng/mL. With 100 ng/mL, hBM-MSCs showed
up-regulation of SCX-A (1.7-fold) at Day 1, TNC (1.3-fold) and TNMD (12-fold) at Day 8. hWJ-MSCs,
at the same dose, showed up-regulation of COL1A1 (3-fold), DCN (2.7-fold), SCX-A (3.8-fold) and
TNC (2.3-fold) after three days of culture. hWJ-MSCs also showed larger proliferation rate and marked
aggregation into a tubular-shaped system at Day 7 (with 100 ng/mL of hGDF-5). Simultaneous to this,
we explored the expression of pro-inflammatory (IL-6, TNF, IL-12A, IL-1β) and anti-inflammatory
(IL-10, TGF-β1) cytokines across for both cell types. hBM-MSCs exhibited a better balance of
pro-inflammatory and anti-inflammatory cytokines up-regulating IL-1β (11-fold) and IL-10 (10-fold)
at Day 8; hWJ-MSCs, had a slight expression of IL-12A (1.5-fold), but a greater up-regulation of IL-10
(2.5-fold). Type 1 collagen and tenomodulin proteins, detected by immunofluorescence, confirming the
greater protein expression when 100 ng/mL were supplemented. In the same conditions, both cell types
showed specific alignment and shape modification with a length/width ratio increase, suggesting their
response in activating tenogenic commitment events, and they both potential use in 3D in vitro
tissue-engineering protocols.
Keywords: Wharton’s Jelly human umbilical cord mesenchymal stem cells (hWJ-MSCs);
Growth Differentiation Factor-5; human bone marrow Mesenchymal Stem Cells (hBM-MSCs);
tenogenic commitment; gene expression; immunofluorescence assay
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1. Introduction
Tendon injuries affect the elderly, active workers, and athletes, resulting in marked economic
healthcare and societal burden [1,2]. Clinical manifestation itself is the result of a long-term interplay
of inflammatory and failed healing response changes [3]. The management of tendon injuries is
challenging, given their limited healing capability, and propensity for a failed healing response [4,5].
Anti-inflammatory drugs are frequently used, but they may actually hinder recovery [6], while in
clinical practice, tissue grafts or prostheses are used for severe injuries [7,8], and cell therapies are
proposed for future application [9–11]. Since the present therapeutic modalities are only partially
effective, a variety of regenerative medicine options are now of great interest. They aim to induce
tendon healing and regeneration, focusing on the role of mesenchymal stem cells therapy and their
derivatives [12,13].
Multipotent Mesenchymal Stem Cells (MSCs) are described as a promising therapeutic tool to
manage tendon conditions in clinical applications [14]. Both in vivo and in vitro studies evidenced
that MSCs can contribute to accelerate and improve the quality of tendon healing [15,16]. The use
of MSCs, in combination with specific growth factors (GFs) is proposed as an innovative treatment
for tendon healing and regeneration [17,18]. Human bone marrow MSCs (hBM-MSCs) have been
extensively characterized [19]. hBM-MSCs are multipotent cells able to differentiate into various types
of mesenchymal cell phenotypes, including osteoblasts, chondroblasts, myoblasts and tenocytes under
specific conditions in vitro [20–22]. Their application in ligament and tendon reconstruction strategies
is promising.
Given the huge gap of knowledge regarding the biology of tendon healing and the sequence of
events and biomolecules involved, a diversity of growth factors are used for tendon research [2,23].
Among these, GDF family members, and more precisely, Growth Differentiation Factor 5 (GDF-5),
have been used successfully to drive tenogenic differentiation. GDF-5 belongs to the TGF-β superfamily,
and it is highly expressed in mesenchymal condensations during skeleton development. GDF-5 is
also called cartilage-derived morphogenetic protein-1 (CDMP-1) and bone-derived morphogenetic
protein-14 (BMP-14). BMPs are deeply involved in the development of endochondral bones [24] and
joints [25], inducing the expression of type 1 collagen in connective tissue [26], with a consequential
important role in tendon healing [27]. Indeed, GDF-5 induces the expression of genes linked to the
neo-tendon phenotype [28–30], and its administration seemed to improve the outcome of tendon
repair [31,32]. However, little is known about the effect of GDF-5 on BM-MSCs transcriptional
regulation and differentiation [22]. Park et al., reported that GDF-5 supplemented (100 ng/mL) culture
media enhanced extracellular matrix (ECM) and tenogenic marker gene expression in adipose-derived
mesenchymal stem cells (ADMSCs) over 12 days [33]. GDF-5 also appeared to induce tenogenic
differentiation of human BM-MSCs when used at a concentration of 100 ng/mL as reflected by
significant increases in total collagen expression and tenogenic marker gene expression (Scleraxis,
Tenascin-C and type 1 collagen at Day 7) [30]. Further, BMP-14 (50–100 ng/mL) significantly increased
tendon marker expression (Scleraxis and Tenomodulin) at mRNA and protein level potentially via
the Sirt1-JNK/Smad1-PPARγ signaling pathway and enhanced by TGF-β3 and VEGF. The association
of BMP-14 with TGF-β3 and VEGF enhanced the tenogenic differentiation of BM-MSCs [22,34].
Pathway analyses on hBM-MSCs treated with GDF-5 highlighted that the potential molecular pathways
involved in GDF-5 induced tenogenic differentiation included cytoskeleton reorganization, cell adhesion,
and extracellular matrix signaling [30]. Further investigation demonstrated apparent cytoskeleton
reorganization, suggesting an important event in tenogenic differentiation [35].
hBM-MSCs have been applied within 3D in vitro models of tendon healing and
regeneration [36–38]. However, given the limited number of hBM-MSCs available for autologous use,
donor site morbidity, and their limited proliferative capacity, it is important to identify alternative
MSCs sources for clinical use and application in tissue-engineered protocols of tendon regeneration.
An alternative tissue source of MSCs is the connective tissue (Wharton’s Jelly) of the human
umbilical cord (hWJ-MSCs) [39,40]. MSCs derived from extra-embryonic tissue, including hWJ-MSCs,
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share several characteristics with adult MSCs, but also retain some features of developmentally
immature stem cell populations, i.e., broad germ layer-spanning differentiation potential, but do
not induce teratomas formation and have a potential application in regenerative medicine that
is not impeded by ethical or legal issues [41]. Moreover, hWJ-MSCs display high proliferation
rates, wide multipotency, hypoimmunogenicity, and unlike hBM-MSCs, require a painless collection
procedure and have faster self-renewal properties, all important features in cell-based therapies [41–43].
hWJ-MSCs have been studied for application in neurological disorders [44], kidney injury [45],
lung injury [46], orthopedic injury [47], liver injury [48], and cancer therapy [49] this far. Mesenchymal
stromal cells isolated from Wharton’s Jelly have been induced to form neurons, myocytes, bone,
cartilage and adipose cells [40,50–53], but, except few recent studies in vivo [54,55], very little is known
about their tenogenic commitment.
The repair process in injured tendons consists of three overlapping phases reported as the
inflammatory, proliferative and remodeling stages [56]. Several cell types are involved in tendon
healing. Pro-inflammatory (M1) and anti-inflammatory (M2) macrophages directly orchestrate tendon
remodeling and by secreting cytokines and growth factors, activate the epithelial-to-mesenchymal
transition (EMT) signaling cascades in the epithelial cells that surround tendon tissue, providing a
source of mesenchymal cells able to repair the injured tissue [56]. Indeed, preclinical and clinical studies
have demonstrated the anti-inflammatory and immunomodulatory potential of MSCs, even though the
mechanisms behind the MSC-based immunomodulation remain a challenge. For example, MSCs can
have different immunomodulatory effects, even on the same types of immune cells, depending on
the disease status. However, both hBM-MSCs and hWJ-MSCs display immunomodulatory properties
and produce large amounts of cytokines and growth factors, connected to the differentiation
processes [41,57,58]. A correlation between GDF-5 and cytokine expression has been noted in
human annulus cells in in vitro disc degeneration models where high levels of two pro-inflammatory
cytokines (IL-1β and TNF-α) leads to a significant down-regulation of GDF-5 [59].
To date, there is no single growth factor (or a cocktail of growth factors) and protocols known
to efficiently induce tenogenic differentiation of stem cells. Given this challenge, determining stem
cell responses to specific dosages of GDF-5 treatment is a fundamental step in addressing tendon
regeneration strategies, tissue-engineering models, and protocols. With the aim of exploring the
possible use of hWJ-MSCs, instead of the gold standard hBM-MSCs, in tissue-engineering protocols for
tendon healing and repair, here, we report the effect of a range of human GDF-5 (hGDF-5) concentrations
on tendon and cytokine gene expression on hWJ-MSCs. hBM-MSCs are included to enable direct
comparison with the research standard. Markers, such as type 1 collagen (COL1A1), Decorin (DCN),
Scleraxis-A (SCX-A), Tenascin-C (TNC) and Tenomodulin (TNMD), and both pro-inflammatory (IL-6,
TNF, IL-12A, IL-1β) and anti-inflammatory (IL-10, TGF-β1) cytokines, were monitored by Real-Time
Polymerase Chain Reaction (RT-PCR). Type 3 collagen (COL3A1) was chosen as a negative marker
because it is basally expressed by stem cells. Morphometric analysis with cells alignment, shape and
length/width ratio coupled with type 1 collagen and tenomodulin proteins detection by quantitative
immunofluorescence completed the proposed study.
2. Results
Detailed flow cytometry characterization of both hBM-MSCs and hWJ-MSCs is reported in
Table S1 (Supplementary Materials) and data acquisition profiles illustrated in Figure 1. All samples
were positive for CD90, CD105, CD73 and negative for CD14, CD34, CD45, HLA-DR in accordance
with previously published data [60]. The proliferation of both cell types was determined during the
experimental time course both with and without hGDF-5 supplementation. No statistically significant
differences in proliferative potential were noted for hBM-MSCs (at Day 16 for untreated cells -NT- it
looks like cells number decreased though) for all the hGDF-5 concentration explored; while hWJ-MSCs
displayed a generally higher proliferation rate (Figure 2) with respect the hBM-MSCs (see NT at Day 7)
that was also positively affected by the growth factor concentrations.
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Figure 2. Proliferation rate of hBM-MSCs and hWJ-MSCs with the human Growth Differentiation
Factor 5 (hGDF-5) dose-dependent effect. The proliferation rate was calculated over different culture
time points and for both untreated cells and hGDF-5 treated cells. Statistically significant differences
are shown as * = p ≤ 0.05; *** = p ≤ 0.005; a = p ≤ 0.05 compared to hBM-MSCs (NT 7d hWJ-MSCs vs.
NT 16d hBM-MSCs; 100 ng 7 d hWJ-MSCs vs. 100 ng 16 d hBM-MSCs); n = 3. (NT = untreated cells;
1 ng = 1 ng/mL of hGDF-5; 10 ng = 10 ng/mL of hGDF-5; 100 ng = 100 ng/mL of hGDF-5; d = days).
Compared to tenoblasts, whose nucleus is ovoid (nuclei length/width ratio <1.5), the overall
tenocytes shape and their nucleus appears elongated with a nuclei length/width ratio >1.7
(Figure 3a) [61,62]. Therefore, hBM-MSCs phenotype commitment was evaluated by nuclear aspect
ratio evolution (length/width: L/W) determined at Day 1, 8 and 16. hBM-MSCs also showed a
specific alignment and shape modification (tenoblast-like) with an L/W ratio ≥1.5 when 100 ng/mL
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of hGDF-5 were supplemented at Day 8 and at Day 16 (Figure 3b and Figure S1 in Supplementary
Materials). Extending our examination of hGDF-5 induction of tenogenic gene expression into
hWJ-MSCs, we noted that cells displayed an aligned phenotype with a tenocyte-like shape, coupled to
the L/W ratio value > 1.7, at Day 7 with 100 ng/mL hGDF-5 supplementation (Figure 3c and Figure S1
in Supplementary Materials).
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Transcriptional analysis of hBM-MSCs supplemented with hGDF-5 (1 ng/mL) revealed
up-regulation of SCX-A (1.3-fold), COL1A1 (1.3-fold), COL3A1 (1.5-fold), DCN (1.2-fold) and TNC
(1.2-fold) after eight days of culture. Up-regulation was transient in nature and had returned to
baseline levels or less by Day 16 (Figure 4a). An hGDF-5 concentration of 10 ng/mL resulted in
a similar transcriptional up-regulation pattern as before, but that peaked at Day 1 and decreased
thereafter (Figure 4b). With 100 ng/mL hGDF-5 supplementation, SCX-A was overexpressed at Day 1
with an up-regulation of 1.7-fold and at Day 8 TNMD (12-fold), DCN (1.4-fold), TNC (1.3-fold),
COL1A1 (1.3-fold), and COL3A1 (1.2-fold) were observed (Figure 4c). All transcripts were
down-regulated thereafter at Day 16.
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hBM-MSCs and hWJ-MSCs with the hGDF-5 dose-dependent effect. The R levels of tenogenic
markers (Type 3 collagen: COL3A1, type 1 collagen: COL1 1, Decorin: DC , Scleraxis- : SCX- ,
Tenomodulin: TNMD, Tenascin-C: TNC) were monitored; three different concentration of hGDF-5
were tested: (a,d) 1 ng/mL, (b,e) 10 ng/mL and (c,f) 100 ng/mL. Untreated cells for matched time-points
selected were used for control purposes. Statistically significant differences are shown as * = p ≤ 0.05,
** = p ≤ 0.01, *** = p ≤ 0.005; a = p ≤ 0.05, b = p ≤ 0.01 compared to NT.
Lo king at RT-qPCR data con erning the expr ssion of tenog ic markers by hWJ-MSCs, 1 ng/mL
was associated with up-regulation of SCX-A (2-fold) and COL1A1 (1.3-fold) at Day 3 and DCN (1.5-fold)
at Day 7 only (Figure 4d). Similarly, 10 ng/mL had little effect on tenogenic gene expression with the
exception of TNC, which increased 1.3-fold at Day 3 (Figure 4e). In contrast to above, and similar to
hBM-MSCs, 100 ng/mL hGDF-5 induced significant up-regulation of SCX-A (3.8-fold), COL1A1 (3-fold),
TNC (2.3-fold), DCN (2.7-fold), and COL3A1 (2.9-fold) at Day 3 (Figure 4f).
Type 1 collagen and tenomodulin protein expression were investigated by quantitative
immunofluorescence assay across both hBM-MSCs and hWJ-MSCs populations. Representative
images and their quantification are shown in Figures 5–7, respectively. The protein expression by
hBM-MSCs and hWJ-MSCs was similar even if the time points explored were necessarily different,
due to the proliferation rate.
With regard to hBM-MSCs, 1 ng/mL of hGDF-5 was associated with no up-regulation of either
protein. Type 1 collagen expression increased by 1.5-fold and 2-fold after treatment with 10 and
100 ng/mL of hGDF-5, respectively, at Day 1 (Figure 5b), and was accompanied by tenomodulin increase
(1.5-fold) after treatment with 10 and 100 ng/mL of hGDF-5 at Day 1 (Figure 5c) (see also Figure S2 in
Supplementary Materials). No cells aggregates were detected along the culture.
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Figure 5. Immunofluorescence (IF) images and quantitative immunofluorescence (q-IF) data illustrating
the effect of different hGDF-5 dose on hBM-MSCs. The panel (a) shows type 1 collagen (red staining)
and tenomodulin (green staining) proteins up to 16 days of culture. Quantitative data on type 1
collagen (b) and tenomodulin (c) proteins were also reported; untreated cells (NT) are illustrated
for comparison purpose. Statistically significant differences are shown as * = p ≤ 0.05; ** = p ≤ 0.01;
a = p ≤ 0.05, b = p ≤ 0.01 compared to NT. (T0 = day 0; NT = untreated cells; 1ng = 1 ng/mL of hGDF-5;
10 ng = 10 ng/mL of hGDF-5; 100 ng = 100 ng/mL of hGDF-5; d = days).
Similar to hBM-MSCs, untreated hWJ-MSCs showed an increase in basal type 1 collagen over time;
however, the protein was only largely overexpressed when 100 ng/mL of hGDF-5 were supplemented.
Moreover, these cells achieved an extremely ordinate alignment towards a specific direction and
showed an elongation of their shape (Figure 6).
Aggregation into 3D spindle-like structures were observed when cells were treated with 1 ng/mL
of hGDF-5 while tubular-like 3D structures were observed when 100 ng/mL of growth factor was used
after seven days of treatment. This tubular structure was already reported by Barboni et al., and is
considered an early organization of cellular 3D structure [63]. Tenomodulin was present within these
spindle-shaped and tubular-shaped aggregates (Figure 7a and Figure S3 in Supplementary Materials).
Quantification of immunofluorescence in hWJ-MSCs images indicated that the type 1 collagen signal
was significantly increased by 1.5-fold and 2.0-fold after treatment with 100 ng/mL of hGDF-5 at Day 1
and Day 7, respectively (Figure 7b). TNMD staining showed a significant increase of 1.5-fold with
100 ng/mL of hGDF-5 at Day 7 (Figure 7c).
Int. J. Mol. Sci. 2020, 21, 5905 8 of 19
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 19 
 
 
Figure 6. IF images illustrating the type 1 collagen expression at different hGDF-5 dose on hWJ-MSCs. 
Protein was stained in red and monitored up to seven days of culture. 
 
Figure 7. Immunofluorescence (IF) images and quantitative immunofluorescence (q-IF) data 
illustrating the effect of different hGDF-5 dose on hWJ-MSCs. The panel (a) shows type 1 collagen 
(red staining) and tenomodulin (green staining) proteins up to seven days of culture. Quantitative 
data on type 1 collagen (b) and tenomodulin (c) proteins were also reported; untreated cells (NT) are 
illustrated for comparison purpose. Statistically significant differences are shown as * = p ≤ 0.05; ** = p 
≤ 0.01; *** = p ≤ 0.005; **** = p ≤ 0.001; a = p ≤ 0.05, b = p ≤ 0.01 compared to NT. (T0 = day 0; NT = 
untreated cells; 1ng = 1 ng/mL of hGDF-5; 10 ng = 10 ng/mL of hGDF-5; 100 ng = 100 ng/mL of hGDF-
5; d = days). 
Figure 6. IF images illustrating the type 1 collagen expression at different hGDF-5 dose on hWJ-MSCs.
Protein was stained in red and monitored up to seven days of culture.
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 8 of 19 
 
 
Figure 6. IF images illustrating the type 1 collage  ex ressio  at different hGDF-5 dose on hWJ-MSCs. 
Protein was stained in red and monitored up to seven days of culture. 
 
Figure 7. Immunofluorescence (IF) images and quantitative immunofluorescence (q-IF) data 
illustrating the effect of different hGDF-5 dose on hWJ-MSCs. The panel (a) shows type 1 collagen 
(red staining) and tenomodulin (green staining) proteins up to seven days of culture. Quantitative 
data on type 1 collagen (b) and tenomodulin (c) proteins were also reported; untreated cells (NT) are 
illustrated for comparison purpose. Statistically significant differences are shown as * = p ≤ 0.05; ** = p 
≤ 0.01; *** = p ≤ 0.005; **** = p ≤ 0.001; a = p ≤ 0.05, b = p ≤ 0.01 compared to NT. (T0 = day 0; NT = 
untreated cells; 1ng = 1 ng/mL of hGDF-5; 10 ng = 10 ng/mL of hGDF-5; 100 ng = 100 ng/mL of hGDF-
5; d = days). 
Figure 7. Immunofluorescence (IF) images and qua titative immunofluorescence (q-IF) data illustrating
the effect of different hGDF-5 dose on hWJ-MSCs. T e panel (a) shows type 1 c llagen (red staini g)
and tenomodulin (green staining) proteins up to sev n days f culture. Quantitative data on type
1 collage (b) and tenomodulin (c) proteins were also repo ted; untrea cells (NT) are illustrated
for comparison purpose. Statistically sign ficant differe ces are shown a a = p ≤ 0.05, b = p ≤ 0.01
compared to NT. (T = day 0; NT = untreated cells; 1ng = 1 ng/mL of hGDF-5; 10 ng = 10 ng/mL of
hGDF-5; 100 ng = 00 ng/mL of hGDF-5; d = days).
Int. J. Mol. Sci. 2020, 21, 5905 9 of 19
A key correlator with tendon repair and MSCs function is immunological responsiveness
and modulation. An hGDF-5 supplementation of 1 ng/mL with hBM-MSCs up-regulated both
pro-inflammatory (IL-6: 4-fold; TNF: 4-fold; IL-12A: 6-fold and IL-1β: 11.5-fold) and anti-inflammatory
(IL-10: 3-fold and TGFβ1: 2.5-fold) cytokines, at Day 8, but not thereafter (Figure 8a). Conversely,
with 10 ng/mL up-regulation of IL-1β (3-fold), only, was noted at Day 8. (Figure 8b). The highest dose
of hGDF-5, 100 ng/mL, was accompanied by significant up-regulation of IL-1β (11-fold) and IL-10
(10-fold) at Day 8, only (Figure 8c).
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ith regard to hWJ-MSCs, evaluation of pro- and anti-inflammatory cytokine expression following
on from hGDF-5 supplementation revealed up-regulation of TNF (~1.5-fold) at Day 3 with 1 ng/mL
(Figure 8d). With 10 ng/mL hGDF-5 supplementation, we again noted up-regulation of TNF (2-fold) at
Day 3 (Figure 8e). Finally, with 100 ng/mL hGDF5 supplementation, we noted significant up-regulation
of IL-12A (1.5-fold), and again, IL-10 (2.5-fold) at Day 3 (Figure 8f).
3. Discussion
We hypothesized that hMSCs from human bone marrow (hBM-MSCs) supplemented with
hGDF-5 would result in up-regulation of genes and proteins consistent with tenogenic differentiation,
and consequently, synthesize and secrete these into the extracellular environment. We further
hypothesized a correlation between hMSCs differentiation and their immunomodulatory activity,
through cytokines expression. We utilized hMSCs, isolated from the umbilical cord (hWJ-MSCs),
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to determine their comparability and behavior in the same conditions (three different concentrations
of hGDF-5) and their possible in vitro use in tendon tissue-engineering. Different doses of hGDF-5
(1 ng/mL, 10 ng/mL and 100 ng/mL) were selected to explore a dose-response effect with regard to
tenogenic commitment and cytokine profile behaviors. As reported in the introduction, the dosage
range explored is generally recognized to have a biological action in vitro within tenogenic commitment
studies [29,30,33]; higher concentrations of 1000 ng/mL seemed to induce cells apoptosis, and were not
discussed in the present study (data not shown).
It is well recognized in the literature that MSCs derived from adult sources have a very low
proliferation potential [64]. Therefore, we were able to explore hBM-MSCs behavior for up to 16 days,
acquiring further data with respect to previous studies reported in the literature which described the
characterization of the same cells against a maximum of 10 days [30]. hWJ-MSCs showed several
similarities, but also some differences. First, given their faster population doubling levels [41–43],
culture longer than seven days was not possible, even though several and considerably lower seed
densities were explored.
Our data are in strong agreement with previous literature in confirming the dose of 100 ng/mL
as optimal for cells commitment toward a tenogenic phenotype. This observation was confirmed
by morphometric analyses, that evidenced nuclei elongation with an increase of nuclei L/W ratio.
hBM-MSCs showed specific tenoblast-like phenotype with an L/W ratio ≥1.5 when 100 ng/mL of
hGDF-5 were supplemented at Day 8 and at Day 16. Instead, a tenocyte-like shape, coupled to the L/W
ratio >1.7 was achieved by hWJ-MSCs after only seven days of treatment when 100 ng/mL of hGDF-5
was supplemented. In the case of hWJ-MSCs, we have not acquired images for intermediate time points,
but, looking at the results of the morphometric analysis in Figure 3c, cells supplemented with 100 ng/mL
of GDF-5 were significantly more elongated than untreated cells at Day 7, and it was not observed in
the control—therefore, it is cannot be considered an effect of confluency. Moreover, we noticed specific
tenogenic markers overexpression by hBM-MSCs at progressively earlier time points when increasing
the growth factor dose.
We elected to monitor the gene expression of TNC and SCX-A because TNC is an ECM glycoprotein
considered an early marker of tenogenic differentiation, abundantly expressed in the musculoskeletal
tissues during embryogenesis [65]. At the same time, SCX-A is a tendon-specific basic helix-loop-helix
transcription factor responsible for the transition of MSCs into tendon progenitors [66]. Both TNC and
SCX-A are particularly responsive to mechanical loading [36,37,65], though we did not study the effects
of mechanical stimuli in the present study. Nevertheless, these markers were up-regulated 1.3-fold at
Day 8 with 1 ng/mL of hGDF-5, suggesting an activation of the tenogenic commitment pathway after
8 days of treatment. The same activation was earlier and more pronounced when 100 ng/mL were
supplemented, with SCX-A overexpressed 1.7-fold at Day 1 and TNC 1.3-fold, at Day 8. DCN was
monitored because is the small leucine-rich proteoglycan involved in the regulation of fibrillogenesis,
and is a fundamental component of the tendon extracellular matrix (ECM), binding to type 1 collagen
fibrils [67]. This protein was again not really overexpressed by hBM-MSCs, except at Day 8 using
100 ng/mL (1.3-fold); this slight increase can be probably explained because the cells do not reach the
complete organization of the ECM in all the experiments considered.
COL1A1 is the major component of tendon tissue (75–85% of the dry mass of tendon), and is
responsible for its mechanical strength [68]. The up-regulation of COL1A1 gene by hBM-MSCs reached
1.5-fold, even when a dose of 100 ng/mL of GDF5 was used in our experimental setting, despite other
authors reporting greater gene expression. Tan et al. [30] reported similar results to the ones evidenced
in this study. Nevertheless, the expression of TNMD was significantly increased, up to 12-fold, at the
concentration of 100 ng/mL of hGDF-5 after eight days of treatment, suggesting cell commitment
versus the specific tendon phenotype. Indeed, TNMD is a type II transmembrane protein, commonly
detected in differentiated tenocytes, and is responsible for the organization of the collagen fibers in the
late phase of tendon development [2,69]. The expression of this gene was not monitored by the same
authors [30], and therefore, a comparison is not possible.
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Furthermore, at 100 ng/mL of hGDF-5, the COL3A1 up-regulation was reduced to only 1.3-fold
after eight days; indeed, this gene is basically overexpressed by hBM-MSCs, and is the main responsible
for fibrotic and scar tissue arrangement [70], and has been reported at the site of rupture of human
tendons [68].
Since an early expression of SCX-A is reported to be a highly specific marker for tenocyte
progenitor cell populations [36] and TNC up-regulation intervenes at the very beginning of tendon
development [11], we can state that PCR data about hWJ-MSCs were favorable with a clear statistically
significant overexpression of SCX-A (3.8-fold), COL1A1 (3-fold), TNC (2.3-fold) and DCN (2.7-fold)
observed with 100 ng/mL of hGDF-5 at Day 3. However, hWJ-MSCs in these conditions also
overexpressed COL3A1, which increased 2.8-fold, compared to the control, at Day 3. The overexpression
of COL3A1 was always higher compared to hBM-MSCs. Nevertheless, we have to take into account that
an early tenogenic commitment can be manifest by over-expression of SCX-A and COL1A1, an expected
outcome of the tenogenic differentiation process, as stated before, because SCX-A regulates tendon
formation and several other characteristics gene expression [64]. SCX-A also regulates the expression
of TNMD [64], but, since TNMD is a marker of mature tenocytes, we suspect that the expression of
this gene was not observed in the case of hWJ-MSCs because it would be further up-regulated if our
experiments were extended to a longer period of time.
The commitment of hBM-MSCs was confirmed by quantitative immunofluorescence assay,
which involved the use of Image J software Application (NHS). This investigation showed a basal
level of type 1 collagen protein which was also evident in control cells, as largely documented [71],
but a great overexpression of this protein was evident when 100 ng/mL were supplemented, while,
tenomodulin protein was evident only at the highest hGDF-5 dose tested. Immunofluorescence (IF)
observations confirmed that cells showed an ordinate aligned pattern along a specific direction at an
hGDF-5 dose of 100 ng/mL at Day 16 with evident shape change in the cells, which became ovoid.
The overall data are in good agreement with the literature, and confirmed that hBM-MSCs are the gold
standard to set in vitro protocols to study tenogenesis or tendon differentiation and healing.
In the case of hBM-MSCs, the overall trend of type 1 collagen is in agreement with published
data, suggesting that the initial phases of tenogenic commitment occurred with different timelines
in MSCs, though sharing similar characteristics. Indeed, Park et al. indicated the same GDF-5
concentration as the best for ADMSCs differentiation over 12 days of cultivation [33]. The same
cell populations of bone marrow MSCs were studied by Tan et al., who described similar results
related to an up-regulation of the same tenogenic markers, even if related to only 10 days of hGDF-5
treatment at a concentration of 100 ng/mL [30]. In the case of hWJ-MSCs, it is difficult to put our
result in another context with published data, because no similar study has been reported to date
on hWJ-MSCs. However, under these experimental conditions, they seem to respond to activating
tenogenic commitment events.
Regarding the mRNA levels of pro-inflammatory and anti-inflammatory cytokines, we noticed in
hBM-MSCs a strong up-regulation of pro-inflammatory cytokines when the lowest concentration of
hGDF-5 was used, above all IL-1β, which reached an 11.5-fold increase at Day 8. However, the strong
up-regulation of IL-1β was better balanced by IL-10 (10-fold increase) when 100 ng/mL of hGDF-5
were used, suggesting that a differentiation process occurs and it could be accompanied by the
immunomodulatory activity of hBM-MSCs in an anti-inflammatory fashion, as reported in the
literature [58]. However, the early tenogenic commitment of hWJ-MSCs observed with 100 ng/mL at Day
3 was accompanied, similarly to hBM-MSCs, by a modulation of the immune response up-regulating
the anti-inflammatory cytokine, such as IL-10 (2.5-fold). Unfortunately, to the best of our knowledge,
this particular aspect of the behaviour of hWJ-MSCs have never been studied, so the hypothetic
correlation between hWJ-MSCs and their immunomodulatory activity needs further investigations.
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4. Materials and Methods
The protocol for the present study and the written informed consent were reviewed and approved
by the Institutional Review Board of San Giovanni di Dio e Ruggi D’Aragona Hospital (Review Board
prot./SCCE n. 24988, March 2015).
4.1. hBM-MSCs Isolation and Harvesting
Human Bone Marrow Mesenchymal Stem Cells (hBM-MSCs) were obtained from the bone marrow
of two male donors (age 37 and 39). Donors provided written informed consent in accordance with
the Declaration of Helsinki to use their filter residual bone marrow aspirate for research purposes.
Briefly, total bone marrow aspirate was directly seeded at a concentration of 50,000 total nucleated
cells/cm2 in T75 plastic flask (BD Falcon, Bedford, MA, USA) in Minimum Essential Medium Alpha
(α-MEM; Corning Cellgro, Manassas, VA, USA) supplemented with 1% GlutagroTM (Corning Cellgro,
Manassas, VA, USA), 10% Fetal Bovine Serum (FBS; Corning Cellgro, Manassas, VA, USA), and 1%
Penicillin/Streptomycin and incubated at 37 ◦C in 5% CO2 atmosphere and 95% relative humidity.
After 72 h, non-adherent cells were removed by media change, and the adherent cells were further fed
twice a week with new media. On day 14, colonies of adherent cells were detached and re-seeded at
4 × 103 cells/cm2 in the same culture conditions. Once cultures reached 70–80% confluence, cells were
detached using 0.05% trypsin-0.53mM EDTA (Corning Cellgro, Manassas, VA, USA) and washed with
Phosphate-buffered saline (PBS) 1× (Corning Cellgro, Manassas, VA, USA), counted using Trypan Blue
(Sigma-Aldrich, Milan, Italy) and sub-cultured at a concentration of 4 × 103 cells/cm2. Flow Cytometry
analysis was performed on cell samples obtained at Passage 1.
4.2. hWJ-MSCs Isolation and Harvesting
Human Wharton’s Jelly Mesenchymal Stem Cells (hWJ-MSCs) were isolated from two donors
(both age 28, unrelated to the male donors) who gave written informed consent in accordance with
the Declaration of Helsinki to use their umbilical cord for research purposes. hWJ-MSCs were
prepared from fresh human umbilical cord obtained during normal spontaneous vaginal delivery.
Briefly, umbilical cord sections, approximately 7.5 cm long, were placed in 0.9% NaCl physiological
solution supplemented with Ampicillin-Sulbactam 1 g + 500 mg, stored at 4 ◦C, and processed within 4
h of collection. The umbilical cord was cut into 2.5 cm segments, and washed in fresh transport media
to remove blood and debris. Each umbilical cord segment was sectioned longitudinally with sterile
scissors, and the visible arteries and veins removed. Each piece was transferred to a tissue culture flask
175 cm2 (BD Falcon, Bedford, MA, USA) containing α-MEM (Corning Cellgro, Manassas, VA, USA)
supplemented with 10% FBS (Corning Cellgro, Manassas, VA, USA), GlutagroTM (Corning Cellgro,
Manassas, VA, USA), and Penicillin-Streptomycin solution. Cultures were incubated at 37 ◦C in a
humidified atmosphere containing 5% CO2. Cell growth was monitored daily with changes in media
twice a week. Upon reaching 100% confluence, cells were detached using 0.05% trypsin-0.53mM EDTA
(Corning Cellgro, Manassas, VA, USA) and were washed with PBS 1× (Corning Cellgro, Manassas,
VA, USA), counted using Trypan Blue (Sigma-Aldrich, St. Louis, MO, USA), and sub-cultured at a
concentration of 4 × 103 cells/cm2. For hWJ-MSCs immunophenotype characterization flow cytometry
analysis was performed on cell samples obtained at Passage 1.
4.3. Flow Cytometry
hBM-MSCs and hWJ-MSCs were detached and counted; 1 × 105 cells were incubated at RT for
20 min with the following directly conjugated mouse-anti human antibodies: CD90 FITC (Beckman
Coulter, Fullerton, CA, USA), CD73 APC (Miltenyi Biotec, Gladbach, Germany), CD105 PE (Beckman
Coulter, Fullerton, CA, USA), CD45 PC7 (Beckman Coulter, Fullerton, CA, USA), HLA class-II
FITC (Beckman Coulter, Fullerton, CA, USA), CD14 PC7 (Beckman Coulter, Fullerton, CA, USA),
and CD34 PE (Beckman Coulter, Fullerton, CA, USA). The isotype-matched immunoglobulins IgG1
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FITC (Beckman Coulter, Fullerton, CA, USA), IgG1 PE (Beckman Coulter, Fullerton, CA, USA), IgG1
APC (Beckman Coulter, Fullerton, CA, USA), and IgG1 PC7 (Beckman Coulter, Fullerton, CA, USA)
were used as negative controls under the same conditions. At least 15,000 total events were acquired
with a BD FACSVerse flow cytometer (Becton Dickinson, BD, NJ, USA). Further analysis and plots
were generated using the BD FACSuite analysis software. Statistics are summarized in Table S1
(Supplementary Materials).
4.4. hGDF-5 Treatment
Each experiment was replicated with n = 3 replicates, using both individual donor cells and
pooling the source. hBM-MSCs and hWJ-MSCs (passage 3) were seeded on coverslips in 12 well-plates
at a concentration of 4 × 103 cells/cm2 and 300 cells/cm2, respectively. The different seeding densities
were to normalize for the differing cell proliferation times where seeding hWJ-MSCs at a density higher
than 300 cells/cm2 saw them reach 90% confluence in less than three days followed by detachment
from the flask surface. Once the cell cultures reached 60% confluence, cells were treated with 1 mL
of culture media supplemented with three different concentrations of recombinant human GDF-5
(PeproTech; UK): 1 ng/mL, 10 ng/mL, and 100 ng/mL. Cells were fed twice a week with new media and
fresh growth factor supplementation. As a consequence of the different proliferation times, hBM-MSCs
were treated for 16 days, and hWJ-MSCs for seven days. Untreated cells for matched time-points were
used for control purposes.
4.5. mRNA Isolation and Gene Expression Profile
Samples were collected at Day 1, 8 and 16 for hBM-MSCs and at Day 1, 3 and 7 for
WJ-MSCs. Total mRNA was extracted using QIAzol® Lysis Reagent (Qiagen, Hilden, Germany),
chloroform (Sigma-Aldrich, Milan, Italy), and the RNeasy Mini Kit (Qiagen, Germany). For each sample,
1 µg of total mRNA was reverse-transcribed using the iScriptTM cDNA synthesis kit (Bio-Rad, Milan,
Italy). Relative gene expression analysis was performed in a LightCycler® 480 Instrument (Roche, Italy),
using the SsoAdvancedTM Universal SYBR® Green Supermix (Bio-Rad) with validated primers for
COL1A1, COL3A1, DCN, SCX-A, TNMD, TNC, IL-6, TNF, IL-12A, IL-1β, IL-10 and TGF-β1 (Bio-Rad),
and following MIQE guidelines [72]. Amplification was performed in a 10 µL final volume, including
2 ng of complementary DNA (cDNA) as a template. The specificity of the amplification products
was addressed via melting curve analysis. Data were normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) expression (reference gene), applying the geNorm method [73] to calculate
reference gene stability between the different conditions (calculated with CFX Manager software;
M < 0.5). Fold changes in gene expression were determined by the 2-∆∆Ct method, and are presented
as relative levels versus untreated cells at each time-point explored. All normalizations were obtained
using untreated control samples cultivated along the investigated time points.
4.6. Morphometric and Proliferation Analysis
Nuclei aspect ratio of hBM-MSCs and hWJ-MSCs was determined at different time points (Day 1,
8 and 16 for hBM-MSCs; Day 1 and 7 for hWJ-MSCs) in culture by analyzing optical microscope images
processed using ImageJ software. Nuclei aspect ratio was determined by measuring and dividing the
length by the width of each nucleus; a total of 50–80 nuclei was measured in each condition using a
minimum of 10 microscope images.
Proliferation of hBM-MSCs and hWJ-MSCs was quantified by counting the number of nuclei in
each time point (Day 0 and 16 for hBM-MSCs; Day 0 and 7 for hWJ-MSCs) and in each condition of
treatment (1 ng/mL, 10 ng/mL and 100 ng/mL of hGDF-5) using a minimum of 10 microscope images.
4.7. Immunofluorescence Assay
Samples were collected at Day 1, 8 and 16 for hBM-MSCs and at Day 1 and 7 for WJ-MSCs.
Cells were fixed with 3.7% formaldehyde for 30 min at room temperature (RT) followed by
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permeabilization with 0.1% Triton X-100 for 5 min and blocking with 1% BSA for 1 h. For type 1 collagen
and tenomodulin staining, cells were incubated overnight at 4 ◦C with a mouse monoclonal anti-type
1 collagen antibody (1:100, Sigma-Aldrich, Milan, Italy) and a rabbit polyclonal anti-tenomodulin
antibody (1:100; Abcam, Cambridge, United Kingdom). Following incubation with the primary
antibody, cells were incubated for 1 h at RT with the DyLight 649 anti-mouse IgG (1:500, BioLegend,
CA, USA) antibody and the Alexa FluorTM 488 goat anti-rabbit IgG (1:500; Thermo Fisher Scientific,
Waltham, MA, USA). Cell nuclei were stained with DAPI solution (1:1000) for 5 min. Images acquisition
was at 63× magnification using an inverted Leica laser-scanning confocal microscope (TCS SP5;
Leica Microsystems, Wetzlar, Germany) equipped with a plan Apo 63x/1.4 NA oil immersion objective.
Image quantification was performed in a blinded manner using image analysis software (ImageJ,
National Institutes of Health, Bethesda, MD, USA) by measuring the red and green areas where type
1 collagen and tenomodulin, respectively, are expressed [74,75]. Original images were converted
from RGB format into a gray scale (16-bit). Then, the average value of pixel intensity (within a range
from 0-dark to 255-white) was calculated for each image. Signal intensity was normalized by the cell
number (e.g., by the amount of cell nuclei revealed by DAPI staining). A minimum of 10 image fields
(with a comparable number of cells in each image) were used for the analysis at each time point for
each experiment.
Data were expressed as fold change relative to untreated cells at matched time-points.
4.8. Statistical Analysis
Statistical analysis was performed using GraphPad Prism software (6.0 for Windows).
For phenotypic analysis, data obtained from multiple experiments (n = 3) are calculated as mean+/-SD
and analyzed for statistical significance using ANOVA test, for independent groups. Differences were
considered statistically significant when p ≤ 0.05.
5. Conclusions
Although the use of autologous stem cells for tendon healing and regeneration has been described
and all tissue-engineering studies indicated bone marrow stem cells as the gold standard to promote
tendon regeneration, hWJ-MSCs have never been studied in this sense and may be an interesting
option. Furthermore, a better understanding of the complex interactions and pathways of the
biomolecules involved in targeted tissue regeneration is necessary to achieve effective therapeutic
outcomes for translation into clinic practice. In this context, hGDF-5 induces cellular events of tenogenic
differentiation that can be time and concentration-dependent. The concentration of 100 ng/mL is more
effective in this sense, correlating with an anti-inflammatory modulation of the response of the immune
cells. This behavior was observed on both stem cells, bone marrow and umbilical cord derived. While
the proliferation of hBM-MSCs is only slightly promoted during hGDF-5 treatment, the hWJ-MSCs
population maintained a high proliferation rate. After seven days and at the dose of 100 ng/mL of
hGDF-5, hWJ-MSCs manifested the up-regulation of tenogenic markers and showed L/W ratio > 1.7.
These preliminary data suggested that, given their properties, hWJ-MSCs could be potentially used in
in vitro tendon tissue-engineering. Further questions, such as the role of proteoglycans expression
in the modulation of tenogenic commitment in combination with GDF-5 signaling and the nature of
epigenetic signature of both cell types have also to be investigated in the future to further understand
the different proliferative rate and markers expression.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/16/5905/s1.
Table S1: Flow cytometry data, Figure S1: Brightfield images of hBM-MSCs and hWJ-MSCs with the hGDF-5
dose-dependent effect, Figure S2: Immunofluorescence images (split channels) illustrating the effect of hGDF-5
treatment on the expression of type 1 collagen and tenomodulin proteins on hBM-MSCs, Figure S3: Immunofluorescence
images (split channels) illustrating the effect of hGDF-5 treatment on the expression of type 1 collagen and tenomodulin
proteins on hWJ-MSCs.
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